Item 5.02.
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
On November 10, 2016,
the board of directors of Guided Therapeutics, Inc. (the “Company”) increased the size of the board from three members
to four and appointed Richard P. Blumberg to fill the newly created vacancy.
Mr. Blumberg has been
a long-time investor in the Company. Since 1978, Mr. Blumberg has been a Principal at Webster, Mrak & Blumberg, a medical-legal
and class action labor litigation firm. He is also currently the Managing Member of Shenghuo Medical, LLC (“Shenghuo”),
a company with licensing rights in several Asian countries for the Company’s LuViva Advanced Cervical Scan, and is the Managing
Member of Elysian Medical, LLC, a company with world-wide rights for certain breast cancer detection technology. He served from
2004 to 2007 as Chief Executive Officer of Energy Logics, a wind power company that developed projects in Alberta, Canada and Montana.
Mr. Blumberg holds a B.S. in Electrical Engineering and Computer Science from the University of Illinois and received a J. D. from
Stanford University. He also brings extensive experience as a venture capitalist specializing in high-tech and life science companies.
As noted above, Mr.
Blumberg serves as a Managing Member of Shenghuo. As previously disclosed in the Company current report on Form 8-K, filed June
8, 2016, on June 5, 2016, the Company entered into a license agreement with Shenghuo pursuant to which the Company granted Shenghuo
an exclusive license to manufacture, sell and distribute the Company’s LuViva Advanced Cervical Cancer device and related
disposables in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo has
been the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extends to manufacturing in those
countries as well. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s
board of directors.
As partial consideration
for, and as a condition to, the license, and to further align the strategic interests of the parties, the Company agreed to issue
a convertible note to Shenghuo, in exchange for an aggregate cash investment of $200,000. The note will provide for a payment to
Shenghuo of $240,000, due upon consummation of any capital raising transaction by the Company within 90 days and with net cash
proceeds of at least $1.0 million. Absent such a transaction, the payment will increase to $300,000 and will be payable by December
31, 2016. The note will accrue interest at 20% per year on any unpaid amounts due after that date. The note will be convertible
into shares of the Company’s common stock at a conversion price per share of $13.92, subject to customary anti-dilution adjustment.
The note will be unsecured, and is expected to provide for customary events of default. The Company will also issue Shenghuo a
five-year warrant exercisable immediately for 17,239 shares of common stock at an exercise price equal to the conversion price
of the note, subject to customary anti-dilution adjustment.
The board has not
yet determined on which board committees, if any, Mr. Blumberg will serve.